| Title |
Venous thromboembolism treatment outcomes in cancer patients and effect of third-party payers on anticoagulant choice
|
|---|---|
| Published in |
Supportive Care in Cancer, August 2016
|
| DOI | 10.1007/s00520-016-3377-x |
| Pubmed ID | |
| Authors |
Gary W. Jean, Katherine Kelly, Jennie Mathew, Eneko Larumbe, Randall Hughes |
| Abstract |
The purpose of this study is to compare the rates of recurrent VTE among cancer patients treated with parenteral agents to the oral anticoagulants. This single-center study was a retrospective chart review of cancer patients with recurrent VTE between January 1, 2009 and December 31, 2014. The primary outcome of the study is the rate of recurrent VTE in patients who received a parenteral anticoagulant (enoxaparin, dalteparin, fondaparinux) versus those who received oral anticoagulants (warfarin and rivaroxaban). Other outcomes investigated include risk factors associated with recurrent VTE events and influence of third-party payer on anticoagulant selection. Four hundred fifty-seven patients met inclusion criteria (178 in the oral anticoagulant group and 279 in the parenteral anticoagulant group). Patients with Medicare were more likely to have received an oral anticoagulant (P = 0.003) and patients with private insurance were more likely to have received a parenteral anticoagulant (P = 0.004). There were 23 recurrent VTE events, 12 events (6.7 %) in the oral anticoagulant group and 11 events (3.94 %) in the parenteral group (P = 0.182). The only significant risk factor noted to increase risk of recurrent VTE was the presence of an IVC filter (adjusted OR 4.38, 95 % CI 1.67-11.53, P = 0.003). While there is no statistical difference in VTE events between groups, the oral anticoagulant group numerically had a higher rate. Important associations were found to have an influence on anticoagulant selection and risk of recurrent VTE. These factors must be incorporated into decision making when treating cancer patients with VTE. |
Mendeley readers
The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Chile | 1 | 3% |
| Turkey | 1 | 3% |
| Denmark | 1 | 3% |
| Unknown | 36 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 13% |
| Student > Master | 5 | 13% |
| Other | 4 | 10% |
| Student > Bachelor | 3 | 8% |
| Student > Ph. D. Student | 3 | 8% |
| Other | 9 | 23% |
| Unknown | 10 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 44% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 8% |
| Nursing and Health Professions | 2 | 5% |
| Immunology and Microbiology | 1 | 3% |
| Business, Management and Accounting | 1 | 3% |
| Other | 2 | 5% |
| Unknown | 13 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 August 2016.
All research outputs
#4,191,837
of 22,883,326 outputs
Outputs from Supportive Care in Cancer
#963
of 4,595 outputs
Outputs of similar age
#72,235
of 343,757 outputs
Outputs of similar age from Supportive Care in Cancer
#21
of 62 outputs
Altmetric has tracked 22,883,326 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,595 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,757 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 62 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.